Enoxaparin Sodium Price Trend and Forecast

About Enoxaparin Sodium

Enoxaparin Sodium is a low molecular weight heparin used as an anticoagulant to prevent and treat blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). It works by inhibiting clotting factors, reducing the risk of clot formation in blood vessels. Administered through injection, it has a more predictable response compared to standard heparin, requiring less frequent monitoring. Enoxaparin is commonly used in surgical procedures and for patients with certain heart conditions to prevent complications related to blood clots.

Enoxaparin Sodium Product Details

Note: Our supplier search experts can assist your procurement teams in compiling and validating a list of suppliers indicating they have products, services, and capabilities that meet your company's needs.

Enoxaparin Sodium Production Processes

1. Enoxaparin Sodium Production by Heparin Sodium: The manufacturing process of Enoxaparin sodium initiates with the extraction of heparin sodium from porcine intestinal mucosa via a multi-step process. The process starts with the conversion of heparin sodium into benzethonium heparinate, followed by the reaction with benzyl chloride to form crude heparin benzyl ester. This ester is precipitated using water and purified with sodium acetate to isolate the sodium salt. The next step involves alkaline depolymerization of the heparin benzyl ester sodium salt with sodium hydroxide to produce crude Enoxaparin Sodium. The compound undergoes purification via bleaching with hydrogen peroxide. The final step is reprecipitation to obtain the final product.

Enoxaparin Sodium Industrial Uses

Enoxaparin Sodium is primarily used in the medical industry as an anticoagulant for the prevention and treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE), and to prevent blood clotting during surgeries. It is also employed in the management of acute coronary syndrome and in patients undergoing hemodialysis. Additionally, it is used for patients with certain types of heart conditions to reduce the risk of clot formation.

Methodology

The displayed pricing data is derived through weighted average purchase price, including contract and spot transactions at the specified locations unless otherwise stated. The information provided comes from the compilation and processing of commercial data officially reported for each nation (i.e. government agencies, external trade bodies, and industry publications).